[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
March 1985

Leiomyoblastoma Associated With Intractable Hypercalcemia and Elevated 1,25Dihydroxycholecalciferol Levels: Treatment by Hepatic Enzyme Induction

Author Affiliations

From the Department of Medicine (Drs Maislos and Sobel) and the Toor Institute (Dr Shany), Soroka University Hospital and the Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.

Arch Intern Med. 1985;145(3):565-567. doi:10.1001/archinte.1985.00360030217040

• A 42-year-old woman, with a previously resected jejunal leiomyoblastoma, was first seen with liver metastases 3½ years after the tumor resection. Intractable malignant hypercalcemia appeared eight months later, together with renal insufficiency. No osteolytic lesions were detected. Levels of parathyroid hormone, cyclic adenosine monophosphate, and 1,25-dihydroxycholecalciferol (1,25[OH]2D) were not useful in distinguishing between the hypercalcemia of malignancy and concurrent hyperparathyroidism. Despite renal insufficiency, hypercalcemia, and subtotal parathyroidectomy, the 1,25(OH)2D levels remained elevated, consistent with the speculation that a tumor product stimulated 1-α-hydroxylation of 25-hydroxycholecalciferol. Phenytoin and phenobarbital (enzyme induction therapy), in combination with phosphorus and glucocorticoids, appeared to be useful in controlling the hypercalcemia.

(Arch Intern Med 1985;145:565-567)